Study Overview
AptarGroup's nasal delivery system is being used in LTR Pharma's Phase II clinical study of SPONTAN®, an investigational intranasal spray for erectile dysfunction treatment. The study focuses on evaluating the safety, tolerability, and pharmacokinetic profile of the spray.
Technical Collaboration
The collaboration involves Aptar Pharma's multidose nasal spray platform, which ensures accurate and consistent dosing. Nanopharm developed and optimized the formulation, providing analytical services to demonstrate drug product and device performance. Noble contributes by delivering human factors and risk management support to enhance regulatory readiness and validate usability.
Strategic Importance
This partnership underscores the importance of robust intranasal delivery systems in clinical development. Aptar Pharma's expertise in formulation, analytical services, and human factors strengthens LTR Pharma's clinical and regulatory pathway for SPONTAN®.
